Cat. No.: HY-N6869

Dehydroabietic acid

Name: Dehydroabietic acid
Brand: MedChemExpress
SKU: HY-N6869
Price: 70.00 USD
Availability: InStock
Rating: 5 (1 reviews)

1 Cited Publications

Avis client

Based on 1 publication(s) in Google Scholar

Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté : 98.52%
CAS No.: 1740-19-8
Formule: C₂₀H₂₈O₂
Masse moléculaire:300.44

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Dehydroabietic acid Chemical Structure

CAS No.: 1740-19-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole (4)
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform Antibiotic :

Voir tous les produits spécifiques à Isoform PPAR :

Cellular Effect

Cell Line	Type	Value	Description	References
5637	IC₅₀	27.59 μM Compound: 1, DHAA	Cytotoxicity against human 5637 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human 5637 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
A549	IC₅₀	>10 μM Compound: 19	Cytotoxicity in human A549 cells by SRB assay Cytotoxicity in human A549 cells by SRB assay	[PMID: 26812172]
A549	IC₅₀	>50 μM Compound: 1; DHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
A549	IC₅₀	55.65 μM Compound: DHAA	Cytotoxic activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
A549	IC₅₀	74.33 μM Compound: 5	Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
A549	IC₅₀	79.46 μM Compound: 4, DHA	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 23988357]
A549	IC₅₀	79.46 μM Compound: DHA	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 24095745]
BEL-7404 tumor cell line	IC₅₀	28.72 μM Compound: DHAA	Cytotoxic activity against human Bel7404 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human Bel7404 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
BEL-7404 tumor cell line	IC₅₀	34.7 μM Compound: DHA	Cytotoxicity against human Bel7404 cells after 48 hrs by MTT assay Cytotoxicity against human Bel7404 cells after 48 hrs by MTT assay	[PMID: 24565905]
EJ	IC₅₀	25.12 μM Compound: 1, DHAA	Cytotoxicity against human EJ cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human EJ cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
HCT-116	IC₅₀	>10 μM Compound: 19	Cytotoxicity in human HCT116 cells by SRB assay Cytotoxicity in human HCT116 cells by SRB assay	[PMID: 26812172]
HCT-116	IC₅₀	30.25 μM Compound: DHAA	Cytotoxic activity against human HCT116 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human HCT116 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
HCT-116	IC₅₀	35.24 μM Compound: DHA	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 24565905]
HEK293	IC₅₀	>100 μg/mL Compound: 31	Inhibition of TNF-alpha-induced NF-kappaB activity in human pNF-kappaB-luc-293 cells Inhibition of TNF-alpha-induced NF-kappaB activity in human pNF-kappaB-luc-293 cells	[PMID: 20022253]
HeLa	IC₅₀	101 μg/mL Compound: 4, dehydroabietic acid	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 19892441]
HeLa	IC₅₀	28.43 μM Compound: 1, DHAA	Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
HeLa	IC₅₀	29.35 μM Compound: DHA	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24565905]
HeLa	IC₅₀	29.35 μM Compound: DHA	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25462253]
HeLa	IC₅₀	30.35 μM Compound: 1; DHA	Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38389893]
HepG2	IC₅₀	>50 μM Compound: 1; DHA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
HepG2	IC₅₀	>50 μM Compound: DHAA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28756264]
HepG2	IC₅₀	76.76 μM Compound: DHA	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24565905]
HepG2	IC₅₀	80.36 μM Compound: 1; DHA	Anticancer activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38389893]
HepG2	IC₅₀	85 μM Compound: 4, DHA	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23988357]
HepG2	IC₅₀	85 μM Compound: DHA	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 24095745]
Jurkat	IC₅₀	25.51 μM Compound: 1, DHAA	Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
Jurkat	IC₅₀	28 μg/mL Compound: 4, dehydroabietic acid	Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 19892441]
L02	IC₅₀	>100 μM Compound: 1; DHA	Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38389893]
L02	IC₅₀	>50 μM Compound: 1; DHA	Antiproliferative activity against human L02 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human L02 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
L02	IC₅₀	>50 μM Compound: DHAA	Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay	[PMID: 28756264]
L6	IC₅₀	101.3 μM Compound: 1	Antiparasitic activity against amastigote stage of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ gene infected in rat L6 cells after 96 hrs by photometric analysis Antiparasitic activity against amastigote stage of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ gene infected in rat L6 cells after 96 hrs by photometric analysis	10.1039/C5MD00498E
L6	IC₅₀	151 μM Compound: 1	Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay	10.1039/C5MD00498E
LoVo	IC₅₀	>25 μg/mL Compound: 31	Antiproliferative activity against human LoVo cells Antiproliferative activity against human LoVo cells	[PMID: 20022253]
MCF7	IC₅₀	>50 μM Compound: DHAA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28756264]
MGC-803	IC₅₀	>100 μM Compound: DHA	Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 25462253]
MGC-803	IC₅₀	>100 μM Compound: 1; DHA	Anticancer activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Anticancer activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38389893]
MGC-803	IC₅₀	>50 μM Compound: 1; DHA	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
NCI-H460	IC₅₀	>50 μM Compound: DHAA	Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 28756264]
NCI-H460	IC₅₀	75.05 μM Compound: DHAA	Cytotoxic activity against human NCI-H460 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human NCI-H460 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
NCI-H460	IC₅₀	80.53 μM Compound: DHA	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 24565905]
NCI-H460	IC₅₀	84.53 μM Compound: 4, DHA	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 23988357]
NCI-H460	IC₅₀	84.53 μM Compound: DHA	Cytotoxicity against human NCI-H460 cells after 3 days by MTT assay Cytotoxicity against human NCI-H460 cells after 3 days by MTT assay	[PMID: 24095745]
NCI-H460	IC₅₀	84.53 μM Compound: DHA	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 25462253]
PC-3	IC₅₀	28.1 μM Compound: 1, DHAA	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
PC-3	IC₅₀	51.31 μM Compound: 5	Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
QGY-7703	IC₅₀	>25 μg/mL Compound: 31	Antiproliferative activity against human QGY7703 cells Antiproliferative activity against human QGY7703 cells	[PMID: 20022253]
RAW264.7	IC₅₀	42.7 μg/mL Compound: 31	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO release Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO release	[PMID: 20022253]
SK-MEL-2	IC₅₀	>10 μM Compound: 19	Cytotoxicity in human SK-MEL-2 cells by SRB assay Cytotoxicity in human SK-MEL-2 cells by SRB assay	[PMID: 26812172]
SK-OV-3	IC₅₀	>10 μM Compound: 19	Cytotoxicity in human SKOV3 cells by SRB assay Cytotoxicity in human SKOV3 cells by SRB assay	[PMID: 26812172]
SK-OV-3	IC₅₀	>50 μM Compound: DHAA	Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 28756264]
SK-OV-3	IC₅₀	65.06 μM Compound: DHAA	Cytotoxic activity against human SKOV3 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human SKOV3 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
SK-OV-3	IC₅₀	65.96 μM Compound: 5	Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
SK-OV-3	IC₅₀	75 μM Compound: DHA	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 24565905]
SK-OV-3	IC₅₀	84 μM Compound: 4, DHA	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 23988357]
SK-OV-3	IC₅₀	84 μM Compound: DHA	Cytotoxicity against human SKOV3 cells after 3 days by MTT assay Cytotoxicity against human SKOV3 cells after 3 days by MTT assay	[PMID: 24095745]
T-24	IC₅₀	>100 μM Compound: 1; DHA	Anticancer activity against human T-24 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Anticancer activity against human T-24 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38389893]
T-24	IC₅₀	>50 μM Compound: 1; DHA	Antiproliferative activity against human T24 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human T24 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
Vero	IC₅₀	20 μg/mL Compound: 5	Concentration required for 50% inhibition of herpes simplex virus 2(HSV-2) using standard plaque reduction assay in vero cells Concentration required for 50% inhibition of herpes simplex virus 2(HSV-2) using standard plaque reduction assay in vero cells	10.1016/S0960-894X(01)80236-5
Vero	IC₅₀	91 μg/mL Compound: 4, dehydroabietic acid	Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay	[PMID: 19892441]

In Vitro

Dehydroabietic acid (0-100 μM, 30 min) decreases NO production in RAW264.7 cells^[1].
Dehydroabietic acid (0-100 μM, 6 h) reduces the mRNA expression levels of inflammatory mediators including inducible nitric oxide (iNOS) and TNF-α in RAW264.7 cells^[1].
Dehydroabietic acid (0-100 μM, 24 h) reduces the MyD88-induced NF-κB and AP-1 transcriptional activities in HEK293T cells^[1].
Dehydroabietic acid (100 μM, 24 h) inactivates both Src and Syk kinases in Src- or Syk-overexpressing HEK293T cells^[1].
Dehydroabietic acid (2.5-15 μM, 4 days) promotes 3T3-L1 adipocyte differentiation in a dose-dependent manner^[2].
Dehydroabietic acid (10 μM, 0-6 days) increases mRNA expression of PPAR-γ target genes (Glut-4 and Cyp4a10) in 3T3-L1 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Western Blot Analysis^[1]

View Protocol

Cell Line:

AW264.7 cells
Concentration:

100 μM
Incubation Time:

5-60 min, 120-240 min
Result:

Blocked the phosphorylation of IκBα at 5 and 15 min.
Reduced c-Jun N-terminal kinase (JNK) phosphorylation.
Reduced phosphorylated levels of mitogen-activated protein kinase kinase 4 (MKK4) and MKK7 at 60 mim.
Decreased the phosphorylation of MKK4 and MKK7 and their downstream protein JNK at 120 and 240 min.

In Vivo

Dehydroabietic acid (10-20 mg/kg, i.g., daily, 9 weeks) alleviates HFD-induced hepatic steatosis and inflammation in HFD mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

HFD mice^[2]
Dosage:

10-20 mg/kg
Administration:

i.g., daily, 9 weeks
Result:

Decreased the levels of liver injury markers, ALT and AST.
Decreased blood TG, TC and LDL-c levels and increased the HDL-c levels.
Activated PPAR-α and its target gene which were reduced by HFD, including acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain and CPT1α.
Decreased mRNA expression of inflammatory factors commonly involved in liver diseases and injury (IL-1β, IL-6, TNF-α, COX-1 and COX-2).
Upregulated mRNA expression of PPAR-γ, Glut-4, Adipor, FSP27, ACOX-1, FABP4, Adiponectin.

Chemical Information

CAS No. 1740-19-8
Appearance Solid
Masse moléculaire 300.44
Formule C₂₀H₂₈O₂
Color White to light yellow
SMILES

O=C([C@]1(C)CCC[C@]2(C)C3=C(CC[C@@]12[H])C=C(C(C)C)C=C3)O
Structure Classification
- Terpenoids
- Diterpenoids
Initial Source
- Plants
- Other Families Extract
- Microorganisms
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

S Afr J Bot

2025 Sep.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (332.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3285 mL

16.6423 mL

33.2845 mL

5 mM

0.6657 mL

3.3285 mL

6.6569 mL

10 mM

0.3328 mL

1.6642 mL

3.3285 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (8.32 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (8.32 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

All Signal Pathway Related Histomorphology

Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Liver Histomorphometry
Liver histomorphometry is a quantitative histological approach used to measure structural alterations in hepatic tissue, including parenchymal loss, steatosis, fibrosis, and vascular remodeling, by combining stained tissue section analysis with stereological or computerized image-based measurements. Classical morphometric frameworks quantify volume fractions of liver compartments and fibrotic regions using systematic sampling and image analysis, enabling objective comparison of pathological changes across experimental groups. These approaches are widely applied in liver cirrhosis and fibrosis studies to reduce subjectivity in histological scoring and improve reproducibility of tissue evaluation. Recent methodological advances integrate automated image analysis and radiomics-based extraction of histological features from standard liver stains (e. g. , H&E and fibrotic stains), enabling quantitative correlation between morphometric features and fibrosis stages in non-alcoholic fatty live

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (286 KB)
SDS (624 KB)
- English - EN (624 KB)
- Français - FR (624 KB)
- Deutsch - DE (624 KB)
- Norwegian - NO (624 KB)
- Español - ES (624 KB)
- Swedish - SV (624 KB)
- Italian - IT (624 KB)
- Korean - KR (624 KB)
- Portuguese - PT (624 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Kim E, et al. Dehydroabietic Acid Suppresses Inflammatory Response Via Suppression of Src-, Syk-, and TAK1-Mediated Pathways. Int J Mol Sci. 2019 Mar 29;20(7):1593. [Content Brief]

[2]. Xie Z, et al. Dehydroabietic acid alleviates high fat diet-induced insulin resistance and hepatic steatosis through dual activation of PPAR-γ and PPAR-α. Biomed Pharmacother. 2020 Jul;127:110155. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3285 mL	16.6423 mL	33.2845 mL	83.2113 mL
	5 mM	0.6657 mL	3.3285 mL	6.6569 mL	16.6423 mL
	10 mM	0.3328 mL	1.6642 mL	3.3285 mL	8.3211 mL
	15 mM	0.2219 mL	1.1095 mL	2.2190 mL	5.5474 mL
	20 mM	0.1664 mL	0.8321 mL	1.6642 mL	4.1606 mL
	25 mM	0.1331 mL	0.6657 mL	1.3314 mL	3.3285 mL
	30 mM	0.1109 mL	0.5547 mL	1.1095 mL	2.7737 mL
	40 mM	0.0832 mL	0.4161 mL	0.8321 mL	2.0803 mL
	50 mM	0.0666 mL	0.3328 mL	0.6657 mL	1.6642 mL
	60 mM	0.0555 mL	0.2774 mL	0.5547 mL	1.3869 mL
	80 mM	0.0416 mL	0.2080 mL	0.4161 mL	1.0401 mL
	100 mM	0.0333 mL	0.1664 mL	0.3328 mL	0.8321 mL

Bioz

Keywords

Dehydroabietic acid

1 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Dehydroabietic acid

Publications Citing Use of MedChemExpress (MCE) Dehydroabietic acid

Voir tous les produits spécifiques à Isoform Antibiotic

Voir tous les produits spécifiques à Isoform PPAR